Back to top

Analyst Maintains Guardant Buy Rating, Citing Shield V2’s Competitive Edge and Strong Commercial Momentum in Colorectal Cancer Screening

William Blair analyst Matt Larew has maintained their bullish stance on GH stock, giving a Buy rating yesterday. Matt Larew has given his Buy ratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Guardant Health, Inc. (GH)